Article
Endocrinology & Metabolism
Delphine Farlay, Sebastien Rizzo, Louis-Georges Ste-Marie, Laetitia Michou, Suzanne N. Morin, Shijing Qiu, Pascale Chavassieux, Roland D. Chapurlat, Sudhaker D. Rao, Jacques P. Brown, Georges Boivin
Summary: Bisphosphonates are commonly used drugs for treating osteoporosis, but long-term use may increase the risk of atypical femur fracture. Research found that patients with AFF had higher bone mineralization levels compared to non-AFF patients, potentially due to the accumulation of bisphosphonates in bone mineral affecting the osteocyte cytoskeleton.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Correction
Orthopedics
Kensaku Abe, Hiroaki Kimura, Norio Yamamoto, Shingo Shimozaki, Takashi Higuchi, Yuta Taniguchi, Takaaki Uto, Hiroyuki Tsuchiya
Summary: A correction to this paper has been published and is accessible through the original article.
BMC MUSCULOSKELETAL DISORDERS
(2021)
Article
Endocrinology & Metabolism
Dennis M. Black, Katherine Condra, Annette L. Adams, Richard Eastell
Summary: Bisphosphonate use is associated with an increased risk of atypical femur fractures (AFFs), but it significantly reduces the risk of hip fractures and osteoporosis. The risk of AFFs varies between Asians and Caucasians, potentially due to differences in femoral geometry.
Article
Cell Biology
Luana Mordask Bonetto, Paola Fernanda Cotait de Lucas Corso, Gabrielle Grosko Kuchar, Jennifer Tsi Gerber, Leonardo Fernandes Cunha, Mohammed Elsalanty, Joao Cesar Zielak, Carla Castiglia Gonzaga, Rafaela Scariot
Summary: This study evaluated the effects of age and sodium alendronate on bone repair of femoral fractures in rats. It found that there were no differences in calcium and alkaline phosphatase levels during the bone repair process, younger animals had lower cross-section but higher flexural strength than older animals, and alendronate did not show associations with these factors.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
(2021)
Article
Endocrinology & Metabolism
Wei Zhou, Jeroen G. J. van Rooij, Denise M. van de Laarschot, Zografia Zervou, Hennie Bruggenwirth, Natasha M. Appelman-Dijkstra, Peter R. Ebeling, Serwet Demirdas, Annemieke J. M. H. Verkerk, M. Carola Zillikens
Summary: A study in the Netherlands found that atypical femur fractures (AFFs) can occur in patients with monogenic bone disorders, even without bisphosphonate use. The study revealed that approximately 25% of AFF patients had clinical features of monogenic bone disorders, including osteogenesis imperfecta and hypophosphatasia. These findings highlight the importance of careful clinical evaluation in AFF patients.
JOURNAL OF BONE AND MINERAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Eleni Tsiantouli, Emmanuel Biver, Thierry Chevalley, Robert Petrovic, Didier Hannouche, Serge Ferrari
Summary: Hypophosphatasia (HPP) is a rare genetic disorder characterized by low serum alkaline phosphatase (ALP). This study found that low ALP values are common in patients with atypical femoral fractures (AFF) and are mainly related to antiresorptive medication. Therefore, low serum ALP has low specificity for HPP among AFF patients.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Article
Orthopedics
Anna Matuszewska, Lukasz Matuszewski, Magdalena Jaszek, Pawel Polak, Szymon Stec
Summary: This study found that the use of bisphosphonate-enriched cement with Pamifos(R) after total knee arthroplasty can reduce the levels of bone turnover markers and cytokines, and may help to decrease the risk of osteoporotic fractures and aseptic revisions.
INTERNATIONAL ORTHOPAEDICS
(2022)
Article
Endocrinology & Metabolism
Yongquan Gao, Xiaochen Liu, Yuan Gu, Deye Song, Muliang Ding, Lele Liao, Junjie Wang, Jiangdong Ni, Guangxu He
Summary: Bisphosphonates do not significantly affect fracture healing time in fracture patients, but they do increase bone density, prevent osteoporosis, and inhibit both bone resorption and formation markers. Early application of bisphosphonates after injury in the appropriate patient population should be considered.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Endocrinology & Metabolism
Elena Tsourdi, M. Carola Zillikens, Christian Meier, Jean-Jacques Body, Elena Gonzalez Rodriguez, Athanasios D. Anastasilakis, Bo Abrahamsen, Eugene McCloskey, Lorenz C. Hofbauer, Nuria Guanabens, Barbara Obermayer-Pietsch, Stuart H. Ralston, Richard Eastell, Jessica Pepe, Andrea Palermo, Bente Langdahl
Summary: Discontinuation of denosumab results in increased bone turnover, rapid bone loss, and risk of multiple vertebral fractures in some patients. Prior bisphosphonate therapy or subsequent antiresorptive treatment may help mitigate the biochemical rebound phenomenon after denosumab discontinuation.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2021)
Review
Endocrinology & Metabolism
Wei Zhou, Jeroen G. J. van Rooij, Peter R. Ebeling, Annemieke J. M. H. Verkerk, M. Carola Zillikens
Summary: Recent studies suggest that atypical femur fractures (AFFs) may be associated with genetic components, with possible genetic variants identified in relation to AFF. Further research is needed to confirm these findings and explore additional gene variants involved in the pathogenesis of AFFs.
CURRENT OSTEOPOROSIS REPORTS
(2021)
Article
Endocrinology & Metabolism
Gareth Crouch, Nitesh D. Dhanekula, Karen Byth, Emma Burn, Sue Lynn Lau, Lillias Nairn, Liza Nery, Jean Doyle, Edward Graham, Andrew Ellis, Roderick J. Clifton-Bligh, Christian M. Girgis
Summary: The Sydney AFF score, based on demographic and femoral geometry variables, provides a quantitative means of identifying female patients with atypical femur fractures. In an independent validation set at a different center in Sydney, a score ≥ 2 demonstrated 73.3% sensitivity and 69.6% specificity for AFF.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Article
Endocrinology & Metabolism
Jeremy Keng Meng Goh, Joyce Suang Bee Koh, Alvin Choong Meng Ng, Meng Ai Png, Tet Sen Howe
Summary: This case report presents a patient who developed bilateral atypical femur fractures after receiving denosumab treatment, despite having no prior history of bisphosphonate use. The patient's symptoms resolved with conservative management, but radiographic abnormalities persisted.
CALCIFIED TISSUE INTERNATIONAL
(2022)
Review
Endocrinology & Metabolism
Swati Rajput, Aditya Dutta, Singh Rajender, Ambrish Mithal, Naibedya Chattopadhyay
Summary: In this meta-analysis, the effectiveness of anti-resorptive therapies (bisphosphonates and denosumab) in preventing/treating bone loss and hypercalcemia in patients with primary hyperparathyroidism (PHPT) was investigated. The results showed that anti-resorptives significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck, increased serum parathyroid hormone (PTH), and decreased serum calcium levels. Bisphosphonates only increased BMD at the lumbar spine, while denosumab increased BMD at both the lumbar spine and femur neck. Alendronate significantly improved bone loss and hypercalcemia in PHPT patients, without altering PTH and calcium levels.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Review
Medicine, General & Internal
Athanasios D. Anastasilakis, Elena Tsourdi, Gaia Tabacco, Anda Mihaela Naciu, Nicola Napoli, Fabio Vescini, Andrea Palermo
Summary: The study found that there is currently insufficient data to prove the significant impact of bone therapies on glucose metabolism in diabetic patients. It is uncertain whether antiosteoporotic drugs have different effects on fracture incidence between diabetic and nondiabetic patients. More research is needed to address these issues and provide stronger recommendations.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Endocrinology & Metabolism
L. N. Raborn, A. B. Burke, D. H. Ebb, M. T. Collins, L. B. Kaban, A. M. Boyce
Summary: Denosumab has shown potential as a treatment for fibrous dysplasia, but limited data exists on its safety and efficacy, especially after discontinuation. This case study provides insights into the duration of efficacy, surrogate treatment markers, and discontinuation effects of denosumab therapy for craniofacial FD. The importance of considering duration of efficacy when treating patients with FD and other nonresectable skeletal neoplasms that require long-term management is highlighted.
OSTEOPOROSIS INTERNATIONAL
(2021)